Ipatasertib - Genentech

Drug Profile

Ipatasertib - Genentech

Alternative Names: GCD 0068; GDC-0068; RG-7440

Latest Information Update: 16 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Array BioPharma
  • Developer Chugai Pharmaceutical; Genentech; Roche Farma
  • Class Antineoplastics; Heterocyclic bicyclo compounds; Piperazines; Pyrimidines; Small molecules
  • Mechanism of Action Proto oncogene protein c-akt inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Breast cancer; Prostate cancer
  • Phase II Gastrointestinal cancer
  • Phase I Solid tumours

Most Recent Events

  • 16 Oct 2017 Interim efficacy data from a phase II LOTUS trial in Breast cancer presented at the 42nd European Society for Medical Oncology Congress (ESMO-2017)
  • 18 Sep 2017 Phase-III clinical trials in Breast cancer (Combination therapy, Late-stage disease, Metastatic disease, First-line therapy) in Spain (PO) (EudraCT2017-001548-36)
  • 18 Sep 2017 Roche plans a phase I/II trial for Breast cancer (Combination therapy, Second-liine therapy or greater) in USA (NCT03280563)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top